Literature DB >> 9364690

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

F Simondon1, M P Preziosi, A Yam, C T Kane, L Chabirand, I Iteman, G Sanden, S Mboup, A Hoffenbach, K Knudsen, N Guiso, S Wassilak, M Cadoz.   

Abstract

A randomized, double-blind trial comparing a diphtheria-tetanus-acellular pertussis vaccine (DTaP) (pertussis toxoid and filamentous hemagglutinin) with a whole-cell vaccine (DTwP) was conducted. A case-contact study was nested in the trial to estimate absolute efficacy. From 1990 through 1994, 4181 children were randomized to receive one of the vaccines at 2, 4, and 6 months. Severe adverse events were monitored weekly during two visits after vaccination. Fewer serious adverse events were observed after DTaP. Surveillance for cough illnesses persisting more than 7 days, in children under 15 years of age, was made by weekly home visits. Examining physicians, blind to vaccination status, took samples for culture and serologic testing. Pertussis was defined as 21 or more days of cough confirmed by culture, serology, or contact with a culture-confirmed person. Beginning 28 days after the third vaccine dose, the overall ratio of pertussis incidence in the DTaP group relative to the DTwP group (RRac/wc) was 1.54 (95% CI, 1.23-1.93). In children younger than 18 months of age, RRac/wc was 1.16 (95% CI, 0.77-1.73) and 1.76 (95% CI, 1.33-2.33) in children older than 18 months, which suggests a shorter duration of protection with the acellular vaccine (P = 0.090). Absolute efficacy estimates derived from the case-contact study confirmed the lower protection afforded by the acellular vaccine compared with the whole-cell vaccine: 31% (95% CI, 7-49) versus 55% against the protocol case definition, and 85% (95% CI, 66-93) versus 96% for the more severe WHO case definition. Although vaccination with DTaP provided a lower degree of protection than the highly effective DTwP, this difference was less prominent before 18 months of age, the customary age for a fourth dose. The safer DTaP vaccine may prove a valuable substitute for whole-cell vaccines when used in a schedule that includes a booster-dose.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364690     DOI: 10.1016/s0264-410x(97)00100-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  59 in total

Review 1.  Concerns about immunisation.

Authors:  H Bedford; D Elliman
Journal:  BMJ       Date:  2000-01-22

2.  Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.

Authors:  C Weber; C Boursaux-Eude; G Coralie; V Caro; N Guiso
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 3.  Bordetella pertussis transmission.

Authors:  Elizabeth A Trainor; Tracy L Nicholson; Tod J Merkel
Journal:  Pathog Dis       Date:  2015-09-14       Impact factor: 3.166

4.  Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

Authors:  James D Cherry; Ulrich Heininger; David M Richards; Jann Storsaeter; Lennart Gustafsson; Margaretha Ljungman; Hans O Hallander
Journal:  Clin Vaccine Immunol       Date:  2010-03-24

5.  Analysis of Bordetella pertussis populations in European countries with different vaccination policies.

Authors:  S C M van Amersfoorth; L M Schouls; H G J van der Heide; A Advani; H O Hallander; K Bondeson; C H W von König; M Riffelmann; C Vahrenholz; N Guiso; V Caro; E Njamkepo; Q He; J Mertsola; F R Mooi
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil.

Authors:  P M Luz; C T Codeço; G L Werneck; C J Struchiner
Journal:  Epidemiol Infect       Date:  2005-11-29       Impact factor: 2.451

7.  Pertussis in rural populations of Saskatchewan (1995 to 2003): incidence, seasonality, and differences among cases.

Authors:  David Vickers; Raúl C Mainar-Jaime; Punam Pahwa
Journal:  Can J Public Health       Date:  2006 Nov-Dec

8.  New developments in BCG vaccine: implications for tuberculosis control.

Authors:  C R MacIntyre
Journal:  Epidemiol Infect       Date:  2007-02       Impact factor: 2.451

9.  Profile: the Niakhar Health and Demographic Surveillance System.

Authors:  Valerie Delaunay; Laetitia Douillot; Aldiouma Diallo; Djibril Dione; Jean-François Trape; Oleg Medianikov; Didier Raoult; Cheikh Sokhna
Journal:  Int J Epidemiol       Date:  2013-08       Impact factor: 7.196

Review 10.  Pertussis re-emergence in the post-vaccination era.

Authors:  Elena Chiappini; Alessia Stival; Luisa Galli; Maurizio de Martino
Journal:  BMC Infect Dis       Date:  2013-03-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.